JW Therapeutics Announces Exclusive Collaboration with 2seventy bio for Autoimmune Disease CAR-T Therapy
Portfolio Pulse from Benzinga Newsdesk
JW Therapeutics has entered into an exclusive collaboration with 2seventy bio for the co-development and commercialization of a CAR-T therapy product for autoimmune diseases in Greater China. JW Therapeutics will handle process development and First-in-Human clinical trials in China, with costs shared by both parties. JW Therapeutics may also negotiate an exclusive license for the product in Greater China and is eligible to receive milestone payments and royalties from 2seventy bio.
January 02, 2024 | 12:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
2seventy bio has entered a collaboration with JW Therapeutics for a CAR-T therapy in Greater China, with potential financial benefits from milestone payments and royalties.
The collaboration with JW Therapeutics opens up a new market for 2seventy bio's CAR-T therapy in Greater China, which is a significant development for the company. The shared costs reduce financial risk, and the potential for milestone and royalty payments provides a financial incentive that could positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80